Switch to:
Also traded in: Germany, Hongkong

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 5.78
SSRX's Cash to Debt is ranked lower than
63% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: 58.56 vs. SSRX: 5.78 )
Ranked among companies with meaningful Cash to Debt only.
SSRX' s Cash to Debt Range Over the Past 10 Years
Min: 0.2  Med: 9999.50 Max: No Debt
Current: 5.78
Equity to Asset 0.82
SSRX's Equity to Asset is ranked higher than
69% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. SSRX: 0.82 )
Ranked among companies with meaningful Equity to Asset only.
SSRX' s Equity to Asset Range Over the Past 10 Years
Min: 0.17  Med: 0.94 Max: 0.97
Current: 0.82
0.17
0.97
Interest Coverage 13.50
SSRX's Interest Coverage is ranked lower than
78% of the 365 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SSRX: 13.50 )
Ranked among companies with meaningful Interest Coverage only.
SSRX' s Interest Coverage Range Over the Past 10 Years
Min: 1.02  Med: 10000.00 Max: 9999.99
Current: 13.5
1.02
9999.99
F-Score: 6
Z-Score: 92.46
M-Score: -2.69
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 36.75
SSRX's Operating margin (%) is ranked higher than
93% of the 730 Companies
in the Global Biotechnology industry.

( Industry Median: -77.71 vs. SSRX: 36.75 )
Ranked among companies with meaningful Operating margin (%) only.
SSRX' s Operating margin (%) Range Over the Past 10 Years
Min: 7.97  Med: 20.74 Max: 28.59
Current: 36.75
7.97
28.59
Net-margin (%) 32.33
SSRX's Net-margin (%) is ranked higher than
93% of the 730 Companies
in the Global Biotechnology industry.

( Industry Median: -78.92 vs. SSRX: 32.33 )
Ranked among companies with meaningful Net-margin (%) only.
SSRX' s Net-margin (%) Range Over the Past 10 Years
Min: 0.7  Med: 17.84 Max: 45.24
Current: 32.33
0.7
45.24
ROE (%) 19.95
SSRX's ROE (%) is ranked higher than
93% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -32.89 vs. SSRX: 19.95 )
Ranked among companies with meaningful ROE (%) only.
SSRX' s ROE (%) Range Over the Past 10 Years
Min: 4.38  Med: 9.37 Max: 53.93
Current: 19.95
4.38
53.93
ROA (%) 16.72
SSRX's ROA (%) is ranked higher than
95% of the 939 Companies
in the Global Biotechnology industry.

( Industry Median: -28.03 vs. SSRX: 16.72 )
Ranked among companies with meaningful ROA (%) only.
SSRX' s ROA (%) Range Over the Past 10 Years
Min: 4.24  Med: 8.89 Max: 20.94
Current: 16.72
4.24
20.94
ROC (Joel Greenblatt) (%) 109.69
SSRX's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. SSRX: 109.69 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SSRX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 23.3  Med: 32.99 Max: 94.53
Current: 109.69
23.3
94.53
Revenue Growth (3Y)(%) 30.00
SSRX's Revenue Growth (3Y)(%) is ranked higher than
83% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. SSRX: 30.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SSRX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 22.7  Med: 34.30 Max: 136.1
Current: 30
22.7
136.1
EBITDA Growth (3Y)(%) 16.40
SSRX's EBITDA Growth (3Y)(%) is ranked higher than
72% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. SSRX: 16.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SSRX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 38.20 Max: 190.2
Current: 16.4
0
190.2
EPS Growth (3Y)(%) 8.40
SSRX's EPS Growth (3Y)(%) is ranked higher than
67% of the 492 Companies
in the Global Biotechnology industry.

( Industry Median: -5.10 vs. SSRX: 8.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
SSRX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 1.5  Med: 28.00 Max: 582.4
Current: 8.4
1.5
582.4
» SSRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with SSRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:OMED, NAS:ARDX, NAS:VYGR, NAS:BLCM, NAS:NDRM, NAS:CTMX, NAS:RVNC, NAS:TRVN, OTCPK:SPHDF, NAS:CYTK, OTCPK:ZLDPF, NAS:SVA, NAS:ARWR, NAS:CGEN, NAS:SGMO, NAS:ARNA, NAS:VSAR, OTCPK:VNLPY, NAS:AKBA, NAS:ASND » details
Traded in other countries:YFK.Germany, 01530.Hongkong,
3SBio, Inc. is a biotechnology company, which focuses on researching, developing, manufacturing and marketing of biopharmaceutical products mainly in China.

3SBio Inc is a fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products mainly in China. 3SBio's recombinant, or genetically engineered, protein-based products and product candidates are designed to address markets with unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases. The company's main products are EPIAO and TPIAO and its legacy products are Intefen and Inleusin. Launched in 1998, EPIAO is an injectable recombinant human erythropoietin, or EPO, that is used to stimulate the production of red blood cells in patients with anemia and to reduce the need for blood transfusions. In 2007, the company received from the SFDA licenses to produce and sell pre-filled syringe EPIAO in 2,000 IU, 3,000 IU, 4,000 IU and 10,000 IU strengths. 3SBio launched TPIAO, its newest internally developed protein-based therapeutic product, in January 2006. This product is a TPO indicated for the treatment of chemotherapy-induced thrombocytopenia, a deficiency of platelets. In addition to EPIAO and TPIAO, it markets two other protein-based therapeutic that had historically been contributors to its overall revenues. Intefen is the company's recombinant interferon alpha-2a product. Intefen is indicated for the treatment of carcinomas of the lymphatic or hematopoietic system, such as lymphoma and leukemia and viral infectious diseases, such as hepatitis C. It launched Intefen in the Chinese market in 1995. The Company's product pipeline, which it expects will be a key contributor to its future growth, consists of six product candidates in various stages of development. 3SBio's main products target markets with unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious disease. The company is currently focused on expanding the indication for its marketed products, developing next generation, enhanced versions of its marketed products and bringing novel protein-based therapeutics to market. 3SBio mainly sources its raw materials from a number of international suppliers through their local distributors. The company's Shenyang-based manufacturing operations consist of bulk manufacturing and formulation, fill and finish activities for the production of EPIAO, TPIAO, Intefen, Inleusin and other product candidates for both clinical and commercial purposes. 3SBio also manufactures its product candidates for clinical trials at this facility. All filling, finishing and packaging activities in relation to its domestic sales are conducted at its Shenyang facility. The company currently markets its products through distribution agreements with local agents in several developing countries, consisting of Egypt, Pakistan, Thailand, Brazil, Mexico, Trinidad and Tobago, Guatemala and Columbia. 3SBio selects its distributors based on their reputation, market coverage and sales experience. It conducts

Ratios

vs
industry
vs
history
P/E(ttm) 28.26
SSRX's P/E(ttm) is ranked higher than
53% of the 254 Companies
in the Global Biotechnology industry.

( Industry Median: 29.09 vs. SSRX: 28.26 )
Ranked among companies with meaningful P/E(ttm) only.
SSRX' s P/E(ttm) Range Over the Past 10 Years
Min: 11.32  Med: 20.26 Max: 35.5
Current: 28.26
11.32
35.5
PE(NRI) 28.26
SSRX's PE(NRI) is ranked higher than
55% of the 229 Companies
in the Global Biotechnology industry.

( Industry Median: 29.71 vs. SSRX: 28.26 )
Ranked among companies with meaningful PE(NRI) only.
SSRX' s PE(NRI) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0
Current: 28.26
Price/Owner Earnings (ttm) 9.29
SSRX's Price/Owner Earnings (ttm) is ranked higher than
87% of the 130 Companies
in the Global Biotechnology industry.

( Industry Median: 34.88 vs. SSRX: 9.29 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
SSRX' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0
Current: 9.29
P/B 2.97
SSRX's P/B is ranked higher than
54% of the 1075 Companies
in the Global Biotechnology industry.

( Industry Median: 3.25 vs. SSRX: 2.97 )
Ranked among companies with meaningful P/B only.
SSRX' s P/B Range Over the Past 10 Years
Min: 0.71  Med: 1.44 Max: 2.66
Current: 2.97
0.71
2.66
P/S 1.46
SSRX's P/S is ranked higher than
92% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 12.77 vs. SSRX: 1.46 )
Ranked among companies with meaningful P/S only.
SSRX' s P/S Range Over the Past 10 Years
Min: 2.62  Med: 4.60 Max: 11.91
Current: 1.46
2.62
11.91
PFCF 7.41
SSRX's PFCF is ranked higher than
88% of the 147 Companies
in the Global Biotechnology industry.

( Industry Median: 27.27 vs. SSRX: 7.41 )
Ranked among companies with meaningful PFCF only.
SSRX' s PFCF Range Over the Past 10 Years
Min: 11.41  Med: 21.49 Max: 100.14
Current: 7.41
11.41
100.14
POCF 5.24
SSRX's POCF is ranked higher than
90% of the 205 Companies
in the Global Biotechnology industry.

( Industry Median: 22.90 vs. SSRX: 5.24 )
Ranked among companies with meaningful POCF only.
SSRX' s POCF Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0
Current: 5.24
EV-to-EBIT 94.82
SSRX's EV-to-EBIT is ranked lower than
90% of the 295 Companies
in the Global Biotechnology industry.

( Industry Median: 20.49 vs. SSRX: 94.82 )
Ranked among companies with meaningful EV-to-EBIT only.
SSRX' s EV-to-EBIT Range Over the Past 10 Years
Min: 0.8  Med: 10.35 Max: 93.7
Current: 94.82
0.8
93.7
EV-to-EBITDA 77.98
SSRX's EV-to-EBITDA is ranked lower than
87% of the 319 Companies
in the Global Biotechnology industry.

( Industry Median: 17.75 vs. SSRX: 77.98 )
Ranked among companies with meaningful EV-to-EBITDA only.
SSRX' s EV-to-EBITDA Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0
Current: 77.98
PEG 0.51
SSRX's PEG is ranked higher than
90% of the 89 Companies
in the Global Biotechnology industry.

( Industry Median: 2.22 vs. SSRX: 0.51 )
Ranked among companies with meaningful PEG only.
SSRX' s PEG Range Over the Past 10 Years
Min: 0.8  Med: 1.38 Max: 2.05
Current: 0.51
0.8
2.05
Current Ratio 4.74
SSRX's Current Ratio is ranked higher than
52% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. SSRX: 4.74 )
Ranked among companies with meaningful Current Ratio only.
SSRX' s Current Ratio Range Over the Past 10 Years
Min: 0.92  Med: 16.55 Max: 35.99
Current: 4.74
0.92
35.99
Quick Ratio 4.63
SSRX's Quick Ratio is ranked higher than
52% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.24 vs. SSRX: 4.63 )
Ranked among companies with meaningful Quick Ratio only.
SSRX' s Quick Ratio Range Over the Past 10 Years
Min: 0.86  Med: 16.10 Max: 35.71
Current: 4.63
0.86
35.71
Days Inventory 128.00
SSRX's Days Inventory is ranked higher than
50% of the 444 Companies
in the Global Biotechnology industry.

( Industry Median: 128.57 vs. SSRX: 128.00 )
Ranked among companies with meaningful Days Inventory only.
SSRX' s Days Inventory Range Over the Past 10 Years
Min: 105.58  Med: 160.73 Max: 236.81
Current: 128
105.58
236.81
Days Sales Outstanding 103.30
SSRX's Days Sales Outstanding is ranked lower than
75% of the 607 Companies
in the Global Biotechnology industry.

( Industry Median: 62.37 vs. SSRX: 103.30 )
Ranked among companies with meaningful Days Sales Outstanding only.
SSRX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 62.95  Med: 76.79 Max: 189.7
Current: 103.3
62.95
189.7
Days Payable 19.49
SSRX's Days Payable is ranked lower than
77% of the 444 Companies
in the Global Biotechnology industry.

( Industry Median: 57.77 vs. SSRX: 19.49 )
Ranked among companies with meaningful Days Payable only.
SSRX' s Days Payable Range Over the Past 10 Years
Min: 19.49  Med: 35.45 Max: 55.76
Current: 19.49
19.49
55.76

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.65
SSRX's Price/Net Cash is ranked lower than
54% of the 739 Companies
in the Global Biotechnology industry.

( Industry Median: 5.19 vs. SSRX: 5.65 )
Ranked among companies with meaningful Price/Net Cash only.
SSRX' s Price/Net Cash Range Over the Past 10 Years
Min: 7.22  Med: 7.22 Max: 7.22
Current: 5.65
Price/Net Current Asset Value 4.01
SSRX's Price/Net Current Asset Value is ranked higher than
57% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 4.83 vs. SSRX: 4.01 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
SSRX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 5.13  Med: 5.13 Max: 5.13
Current: 4.01
Price/Tangible Book 3.37
SSRX's Price/Tangible Book is ranked higher than
56% of the 1012 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. SSRX: 3.37 )
Ranked among companies with meaningful Price/Tangible Book only.
SSRX' s Price/Tangible Book Range Over the Past 10 Years
Min: 4.31  Med: 4.31 Max: 4.31
Current: 3.37
Price/Graham Number 2.04
SSRX's Price/Graham Number is ranked higher than
63% of the 214 Companies
in the Global Biotechnology industry.

( Industry Median: 2.88 vs. SSRX: 2.04 )
Ranked among companies with meaningful Price/Graham Number only.
SSRX' s Price/Graham Number Range Over the Past 10 Years
Min: 2.61  Med: 2.61 Max: 2.61
Current: 2.04
Earnings Yield (Greenblatt) (%) 1.10
SSRX's Earnings Yield (Greenblatt) (%) is ranked higher than
77% of the 1169 Companies
in the Global Biotechnology industry.

( Industry Median: -9.30 vs. SSRX: 1.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SSRX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.1  Med: 9.70 Max: 120.8
Current: 1.1
1.1
120.8
Forward Rate of Return (Yacktman) (%) 23.24
SSRX's Forward Rate of Return (Yacktman) (%) is ranked higher than
65% of the 114 Companies
in the Global Biotechnology industry.

( Industry Median: 14.20 vs. SSRX: 23.24 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
SSRX' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 2.7  Med: 18.30 Max: 22.7
Current: 23.24
2.7
22.7

More Statistics

Short Percentage of Float0.00%
52-Week Range $10.15 - 16.70
Shares Outstanding (Mil)22.08
» More Articles for SSRX

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
No related articles found.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)